Point Biopharma’s radiopharmaceutical prostate cancer therapy, PNT2002, reached its main goal in a clinical trial, yet questions were raised about its effectiveness against a similar Novartis drug. The Point therapy showed a 29% reduction in the risk of radiographic progression or death compared to control drugs, but was less effective than expected, potentially impacting the commercial viability of PNT2002. Point and partner Lantheus plan to report further data next year.
M&S still rebuilding after April cyber incident – Digital Watch Observatory
Summarize this content to a maximum of 60 words: M&S still rebuilding after April cyber incident Digital Watch Observatory
